Doximity Q1 revenue beats analyst estimates
DOCS•Q2 outlook and updated FY27 guidance
Doximity sees Q2 revenue between $170 million and $171 million. The company expects Q2 adjusted EBITDA between $80.5 million and $81.5 million. Doximity updated FY27 revenue guidance to $671 million to $681 million.
Key reported figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q1 Revenue | Beat | $156.62 million | $151.73 million (18 analysts) |
| Q1 Net Income | $24.32 million | ||
| Q1 Adjusted EBITDA | Beat | $74.8 million | $69.56 million (18 analysts) |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 12 "hold" and 1 "sell" or "strong sell". The average consensus recommendation for the software peer group is "buy". Wall Street's median 12-month price target for Doximity, Inc. is $23.50, about 8.6% above its August 5 closing price of $21.63. The stock recently traded at 15 times the next 12-month earnings versus a P/E of 15 three months ago.
Engagement and AI features drove results
- User engagement - The company reported record platform engagement and more than 30% year-over-year growth in workflow active prescribers.
- - The company highlighted increased usage of AI-powered clinical tools, including top performance of its clinical AI assistant in a benchmark.
